Haya therapeutics inc
WebHAYA Therapeutics SA Nov 2024 - Apr 2024 1 year 6 months. President & CEO BioTheryX, Inc. Nov 2024 - Jul 2024 9 months. San Diego, … WebResearch interests: NGS, fibrosis, inflammation, high throughput therapeutics, bioinformatics, data analytics Learn more about Heather …
Haya therapeutics inc
Did you know?
WebSep 2004 - Jun 200510 months. New Orleans, Louisiana, United States. Research into the mechanisms of chronic pain and treatment using … WebFunding. HAYA Therapeutics has raised a total of $25.3M in funding over 8 rounds. Their latest funding was raised on Feb 9, 2024 from a Seed round. HAYA Therapeutics is funded by 9 investors. Viva BioInnovator and …
WebOur goal is to transform the lives of patients with rare genetic disease. By intervening early, we believe we will be able to restore the function of aberrant genes before the patients experience irreversible declines in function. Our technology platform is modular in nature; our initial product candidates will leverage our existing knowledge ... WebMay 21, 2024 · HAYA Therapeutics, SA, société développant des médicaments de précision qui ciblent les ARN longs non codants (lncRNA) spécifiques aux tissus et aux c
WebFeb 15, 2024 · This is why I co-founded HAYA Therapeutics. HAYA’s approach targets these important information processing features within our source code, long non-coding RNAs (lncRNAs), for the safer and more ... WebFeb 16, 2024 · HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding …
WebMay 21, 2024 · Haya Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs, said it closed a $20 million (CHF 18 million) seed round to advance its pipeline targeting anti-fibrotics for many tissues. Photo: Samir Ounzain, co-founder and CEO of Haya Therapeutics. Broadview Ventures led the …
WebMar 14, 2024 · 天眼查为您提供HAYA Therapeutics SA的企业信息查询服务，查询HAYA Therapeutics SA工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、 … farwell reportWebMay 20, 2024 · HAYA Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), closed its CHF 18 million Seed round. The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq, and Viva BioInnovator. … free tree testing toolsWebMay 20, 2024 · The latest Tweets from HAYA Therapeutics (@HAYA_lncRNA). Pioneering the next generation of anti-fibrotic therapies by targeting long non-coding RNAs to … free tree vectorWebMay 21, 2024 · Haya Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs, said it closed a $20 million (CHF 18 … free trees washington stateWebMay 20, 2024 · HAYA Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic … free tree with roots graphicsWebMay 20, 2024 · Swiss precision medicine biotech Haya Therapeutics is coming out of stealth today with nearly $20 million, or CHF 18 million, in seed funding to boost its anti-fibrotic therapies. The preclinical ... farwell report 1995farwell report 1994